Axitinib: Phase III data

The open-label, international Phase III AXIS 1032 trial in about 720 patients showed that twice-daily axitinib as second-line therapy met the primary endpoint of significantly improving PFS vs. twice-daily Nexavar sorafenib. Pfizer said it plans to work with health authorities to determine possible regulatory options for axitinib for use in patients with advanced RCC. ...